CurrentCignaPolicy N/A

Hereditary Angioedema - Ruconest Drug Quantity Management Policy Per Days

Defines quantity limits, one-time override rules, and coverage criteria for Ruconest IV vials for treatment of hereditary angioedema attacks for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyHereditary Angioedema - Ruconest Drug Quantity Management Policy Per Days

Policy CodePolicy N/A

Change TypeRevised quantity limits and override duration

Effective DateN/A

Next Review DateFeb 9, 2024

Key ActionAt retail, set approval quantity = prior vials in 28-day lookback + 16 vials; at home delivery, use 84-day lookback + 16 vials; one override may be approved once every 30 days.

SourceLink

POLICY UPDATE CHANGES

One-time approvals are provided for 30 days in duration.

Override quantity for additional Ruconest vials updated to approve 16 additional vials (previously 4).

2,100units per single-use vial

16 vialsRetail max / 28 days

48 vialsHome delivery max / 84 days

≤4,200 Uper dose limit

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Drug Quantity Limits and Override

Covered as medically necessary when quantity limits or allowable override criteria are met

Standard quantity limits: At retail, maximum 16 vials per 28 days; at home delivery, maximum 48 vials per 84 days.Retail=16 vials/28d; Home delivery=48 vials/84d

Product supplied as 2,100-unit single-use vials.

One-time override for additional attacks: If the patient requires additional doses of Ruconest to treat a subsequent attack of hereditary angioedema (HAE), approve a one-time override for 16 additional vials.+16 vials

At retail, approval quantity = vials received in past 28 days + 16; at home delivery, approval quantity = vials received in past 84 days + 16. ONE override may be approved ONCE every 30 days; one-time approvals are provided for 30 days in duration.

Any request for Ruconest quantities that does not meet the Drug Quantity Management limits or the specified override criteria is considered not medically necessary. The policy’s Drug Quantity Limits define allowable quantities for retail and home delivery; exceptions must follow the documented one-time override rules to be eligible for coverage.

Requests that exceed the defined maximum quantities — namely, more than 16 vials per 28 days for retail dispensing or more than 48 vials per 84 days for home delivery — and that do not meet the policy’s one-time override criteria are considered not medically necessary and will be denied.

Coding and Dose Limits

Quantity / productNDC

NDC	Not specified in document; product-level quantity limits provided

Dose and vial thresholds

Per-dose dosing limitRecommended dose 50 units/kg; do not exceed 4,200 units per dose; a second dose may be given if symptoms persist but no more than two doses in 24 hours.

Vial strengthSingle-use vial contains 2,100 units of Ruconest (lyophilized powder for reconstitution).

Retail maximum (28-day)Maximum 16 vials per 28 days for retail dispensing.

Home delivery maximum (84-day)Maximum 48 vials per 84 days for home delivery.

One-time override quantityApprove a one-time override for 16 additional vials when needed for a subsequent HAE attack; ONE override may be approved once every 30 days.

Provider Actions and Operational Notes

Note

Drug Quantity Management / one-time override

One-time override rule applies at point of service. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the criteria. One-time approvals are provided for 30 days in duration.

Documentation Required

Provider operational note — inventory and documentation

Provider operational note: At point of service, verify the patient's recent dispensation history before submitting an override request. Confirm vial counts from the payer's retail 28-day or home delivery 84-day lookback prior to calculating approval quantity. Document the clinical need for additional doses and the date(s) of prior dispensations to support the one-time override.

Background

Ruconest is a recombinant C1-esterase inhibitor indicated for treatment of acute hereditary angioedema (HAE) attacks in adults and adolescents. The recommended dose is 50 units/kg up to a maximum of 4,200 units administered intravenously; a second dose may be given if symptoms persist, but no more than 2 doses in 24 hours. Ruconest is supplied as single-use vials containing 2,100 units per vial. Clinical guidance supports access to at least two standard on-demand doses for HAE patients.

Definitions and Guidelines

Ruconest — recombinant C1-INH

DefinitionRuconest is a recombinant C1 esterase inhibitor (C1-INH) indicated for treatment of acute hereditary angioedema (HAE) attacks in adults and adolescents.

IndicationTreatment of acute HAE attacks; on‑demand therapy administered intravenously.

AdministrationDelivered as an intravenous injection after reconstitution from single‑use 2,100‑unit vials; recommended dose 50 U/kg up to 4,200 units.

US HAE Medical Advisory Board guideline (2020)

Guideline recommendationUS HAE Medical Advisory Board (2020) recommends all patients with laboratory‑confirmed HAE should have access to at least two standard doses of an approved on‑demand medication.

RationaleOn‑demand treatment is most effective when administered early after attack onset.

Prior Authorization

Dosing and vial information

Dosing and vial information: The recommended dose of Ruconest is 50 units/kg up to a maximum of 4,200 units administered as a slow IV injection over approximately five minutes. If symptoms persist, an additional dose at the recommended dose level may be administered; do not exceed 4,200 units per dose. No more than two doses should be administered within a 24-hour period. Ruconest is supplied in single-use 25 mL vials containing 2,100 units per vial; each carton contains one vial. When calculating quantities for coverage or overrides, account for vial units (2,100 units per vial) relative to the patient’s weight-based dosing and the limits above.

Recommended dose: 50 units/kg, up to 4,200 units per dose
Maximum: Do not exceed 4,200 units per dose; max two doses in 24 hours
Vial size: single-use 25 mL vial with 2,100 units per vial